Advanced Magnetics Combidex
Magnetic resonance imaging contrast agent is "approvable" at FDA for diagnosis of lymph node disease, but not for a second indication for imaging of the liver and spleen. The company will meet with FDA to clarify the agency's questions raised in the June 21 letter. The company is seeking a partner to market Combidex to oncologists, radiologists and surgeons. The NDA was submitted Dec. 21, 1999
You may also be interested in...
Advanced Magnetics' imaging agent Combidex may require additional study following a negative advisory committee review
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011